Key Corporate Partnerships

In 2018, we entered into non-exclusive global collaboration agreements with Junshi and Innovent to conduct safety run-in studies to evaluate the safety of fruquintinib or surufatinib in combination with PD-1 monoclonal antibodies being developed by Junshi (Tuoyi) and Innovent (Tyvyt).